Sanara Medtech Inc Financials
This page shows Sanara Medtech Inc (SMTI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Sanara Medtech Inc has an operating margin of -7.8%, meaning the company retains $-8 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -6.5% the prior year.
Sanara Medtech Inc's revenue surged 33.4% year-over-year to $86.7M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Sanara Medtech Inc carries a low D/E ratio of 0.78, meaning only $0.78 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 82/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 2.18, Sanara Medtech Inc holds $2.18 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 67/100.
While Sanara Medtech Inc generated -$24K in operating cash flow, capex of $206K consumed most of it, leaving -$230K in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Sanara Medtech Inc passes 4 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Sanara Medtech Inc generates $0.00 in operating cash flow (-$24K OCF vs -$9.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Sanara Medtech Inc earns $-2.1 in operating income for every $1 of interest expense (-$6.7M vs $3.1M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Sanara Medtech Inc generated $86.7M in revenue in fiscal year 2024. This represents an increase of 33.4% from the prior year.
Sanara Medtech Inc's EBITDA was -$1.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 231.8% from the prior year.
Sanara Medtech Inc generated -$230K in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 93.5% from the prior year.
Sanara Medtech Inc reported -$9.7M in net income in fiscal year 2024. This represents a decrease of 124.6% from the prior year.
Sanara Medtech Inc earned $-1.14 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 119.2% from the prior year.
Sanara Medtech Inc held $15.9M in cash against $30.7M in long-term debt as of fiscal year 2024.
Sanara Medtech Inc had 9M shares outstanding in fiscal year 2024. This represents an increase of 2.6% from the prior year.
Sanara Medtech Inc's gross margin was 90.6% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 2.7 percentage points from the prior year.
Sanara Medtech Inc's operating margin was -7.8% in fiscal year 2024, reflecting core business profitability. This is down 1.3 percentage points from the prior year.
Sanara Medtech Inc's net profit margin was -11.2% in fiscal year 2024, showing the share of revenue converted to profit. This is down 4.5 percentage points from the prior year.
Sanara Medtech Inc invested $5.7M in research and development in fiscal year 2024. This represents an increase of 38.0% from the prior year.
Sanara Medtech Inc invested $206K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 22.4% from the prior year.
SMTI Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $26.3M+1.9% | $25.8M+10.2% | $23.4M-10.9% | $26.3M+21.4% | $21.7M+7.5% | $20.2M+8.8% | $18.5M+4.8% | $17.7M |
| Cost of Revenue | $1.9M-3.3% | $1.9M+5.6% | $1.8M-18.4% | $2.2M+12.9% | $2.0M-0.8% | $2.0M+6.3% | $1.9M+5.7% | $1.8M |
| Gross Profit | $24.5M+2.4% | $23.9M+10.6% | $21.6M-10.2% | $24.1M+22.2% | $19.7M+8.4% | $18.2M+9.0% | $16.6M+4.7% | $15.9M |
| R&D Expenses | $1.0M-18.1% | $1.3M+12.9% | $1.1M-62.7% | $3.0M+281.1% | $784K-20.5% | $986K+4.2% | $946K+45.2% | $652K |
| SG&A Expenses | $19.9M-7.8% | $21.6M+0.5% | $21.4M-10.6% | $24.0M+37.7% | $17.4M-8.1% | $19.0M+17.1% | $16.2M-0.9% | $16.3M |
| Operating Income | $2.9M+9482.5% | -$31K+98.5% | -$2.1M+32.4% | -$3.1M-495.3% | $779K+127.0% | -$2.9M-88.3% | -$1.5M-577.8% | -$226K |
| Interest Expense | $1.8M+1.5% | $1.8M+36.0% | $1.3M+2.2% | $1.3M+39.0% | $928K+44.0% | $644K+141.0% | $267K+2244.2% | $11K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$30.4M-1409.7% | -$2.0M+42.9% | -$3.5M-129.2% | -$1.5M+46.2% | -$2.9M+18.4% | -$3.5M-98.6% | -$1.8M-643.8% | -$237K |
| EPS (Diluted) | $-3.40-1378.3% | $-0.23+43.9% | $-0.41 | N/A | $-0.34+17.1% | $-0.41-95.2% | $-0.21 | N/A |
SMTI Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $71.1M-28.0% | $98.8M+2.5% | $96.4M+9.4% | $88.1M-0.5% | $88.5M+20.7% | $73.4M+3.5% | $70.9M-4.0% | $73.9M |
| Current Assets | $31.2M-7.3% | $33.7M-8.6% | $36.8M+10.6% | $33.3M+4.4% | $31.9M+53.3% | $20.8M+21.1% | $17.2M-9.6% | $19.0M |
| Cash & Equivalents | $14.9M-11.9% | $17.0M-18.0% | $20.7M+30.3% | $15.9M-2.5% | $16.3M+164.7% | $6.2M+117.5% | $2.8M-45.1% | $5.1M |
| Inventory | $3.4M-3.6% | $3.5M+11.2% | $3.2M+14.8% | $2.8M-8.5% | $3.0M-15.6% | $3.6M-15.7% | $4.2M-10.4% | $4.7M |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | $3.6M0.0% | $3.6M0.0% | $3.6M0.0% | $3.6M0.0% | $3.6M0.0% | $3.6M0.0% | $3.6M0.0% | $3.6M |
| Total Liabilities | $64.9M+2.5% | $63.4M+6.1% | $59.7M+21.4% | $49.2M+0.2% | $49.1M+53.5% | $32.0M+14.6% | $27.9M-4.7% | $29.3M |
| Current Liabilities | $17.4M+16.7% | $14.9M+12.0% | $13.3M-13.1% | $15.3M+6.6% | $14.3M+24.0% | $11.6M-9.3% | $12.7M-7.4% | $13.8M |
| Long-Term Debt | $45.1M+2.0% | $44.2M+1.9% | $43.4M+41.4% | $30.7M+2.0% | $30.1M+109.3% | $14.4M+63.9% | $8.8M-3.8% | $9.1M |
| Total Equity | $6.1M-82.6% | $35.4M-3.5% | $36.7M-6.9% | $39.4M-1.0% | $39.8M-4.6% | $41.7M-3.7% | $43.3M-3.4% | $44.8M |
| Retained Earnings | -$73.7M-70.2% | -$43.3M-4.8% | -$41.3M-9.3% | -$37.8M-4.2% | -$36.2M-8.6% | -$33.4M-11.7% | -$29.9M-6.6% | -$28.0M |
SMTI Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $2.2M-18.3% | $2.7M+233.3% | -$2.0M-314.5% | $932K-54.5% | $2.1M+245.2% | -$1.4M+11.4% | -$1.6M-87.9% | -$849K |
| Capital Expenditures | $1.1M-39.8% | $1.8M+2.2% | $1.7M+2286.9% | $72K+693.4% | $9K-84.5% | $59K-10.7% | $66K+21.3% | $54K |
| Free Cash Flow | $1.1M+23.7% | $903K+124.3% | -$3.7M-532.8% | $860K-57.9% | $2.0M+238.8% | -$1.5M+11.4% | -$1.7M-83.9% | -$903K |
| Investing Cash Flow | -$3.4M+12.9% | -$3.9M+24.2% | -$5.2M-3884.7% | -$130K+98.0% | -$6.4M-10718.3% | -$59K+10.7% | -$66K-21.3% | -$54K |
| Financing Cash Flow | -$775K+68.6% | -$2.5M-120.6% | $12.0M+1098.2% | -$1.2M-108.3% | $14.4M+201.1% | $4.8M+827.5% | -$659K-254.4% | -$186K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | $0 | $0 | N/A | N/A | N/A |
SMTI Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 92.9%+0.4pp | 92.5%+0.3pp | 92.2%+0.7pp | 91.5%+0.6pp | 90.8%+0.8pp | 90.0%+0.2pp | 89.8%-0.1pp | 89.9% |
| Operating Margin | 11.2%+11.3pp | -0.1%+8.8pp | -8.9%+2.8pp | -11.7%-15.3pp | 3.6%+17.9pp | -14.3%-6.0pp | -8.3%-7.0pp | -1.3% |
| Net Margin | -115.5%-107.7pp | -7.8%+7.2pp | -15.0%-9.2pp | -5.9%+7.3pp | -13.2%+4.2pp | -17.4%-7.9pp | -9.5%-8.2pp | -1.3% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 241.6% |
| Return on Assets | -42.8%-40.7pp | -2.0%+1.6pp | -3.7%-1.9pp | -1.8%+1.5pp | -3.2%+1.5pp | -4.8%-2.3pp | -2.5%-2.2pp | -0.3% |
| Current Ratio | 1.80-0.5 | 2.26-0.5 | 2.77+0.6 | 2.18-0.0 | 2.23+0.4 | 1.80+0.5 | 1.35-0.0 | 1.38 |
| Debt-to-Equity | 7.33+6.1 | 1.25+0.1 | 1.18+0.4 | 0.78+0.0 | 0.76+0.4 | 0.34+0.1 | 0.200.0 | 0.20 |
| FCF Margin | 4.2%+0.8pp | 3.5%+19.4pp | -15.9%-19.1pp | 3.3%-6.2pp | 9.4%+16.7pp | -7.3%+1.7pp | -9.0%-3.9pp | -5.1% |
Similar Companies
Frequently Asked Questions
What is Sanara Medtech Inc's annual revenue?
Sanara Medtech Inc (SMTI) reported $86.7M in total revenue for fiscal year 2024. This represents a 33.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Sanara Medtech Inc's revenue growing?
Sanara Medtech Inc (SMTI) revenue grew by 33.4% year-over-year, from $65.0M to $86.7M in fiscal year 2024.
Is Sanara Medtech Inc profitable?
No, Sanara Medtech Inc (SMTI) reported a net income of -$9.7M in fiscal year 2024, with a net profit margin of -11.2%.
What is Sanara Medtech Inc's earnings per share (EPS)?
Sanara Medtech Inc (SMTI) reported diluted earnings per share of $-1.14 for fiscal year 2024. This represents a -119.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Sanara Medtech Inc's EBITDA?
Sanara Medtech Inc (SMTI) had EBITDA of -$1.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Sanara Medtech Inc have?
As of fiscal year 2024, Sanara Medtech Inc (SMTI) had $15.9M in cash and equivalents against $30.7M in long-term debt.
What is Sanara Medtech Inc's gross margin?
Sanara Medtech Inc (SMTI) had a gross margin of 90.6% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Sanara Medtech Inc's operating margin?
Sanara Medtech Inc (SMTI) had an operating margin of -7.8% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Sanara Medtech Inc's net profit margin?
Sanara Medtech Inc (SMTI) had a net profit margin of -11.2% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Sanara Medtech Inc's free cash flow?
Sanara Medtech Inc (SMTI) generated -$230K in free cash flow during fiscal year 2024. This represents a 93.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Sanara Medtech Inc's operating cash flow?
Sanara Medtech Inc (SMTI) generated -$24K in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Sanara Medtech Inc's total assets?
Sanara Medtech Inc (SMTI) had $88.1M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Sanara Medtech Inc's capital expenditures?
Sanara Medtech Inc (SMTI) invested $206K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Sanara Medtech Inc spend on research and development?
Sanara Medtech Inc (SMTI) invested $5.7M in research and development during fiscal year 2024.
How many shares does Sanara Medtech Inc have outstanding?
Sanara Medtech Inc (SMTI) had 9M shares outstanding as of fiscal year 2024.
What is Sanara Medtech Inc's current ratio?
Sanara Medtech Inc (SMTI) had a current ratio of 2.18 as of fiscal year 2024, which is generally considered healthy.
What is Sanara Medtech Inc's debt-to-equity ratio?
Sanara Medtech Inc (SMTI) had a debt-to-equity ratio of 0.78 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Sanara Medtech Inc's return on assets (ROA)?
Sanara Medtech Inc (SMTI) had a return on assets of -11.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Sanara Medtech Inc's cash runway?
Based on fiscal year 2024 data, Sanara Medtech Inc (SMTI) had $15.9M in cash against an annual operating cash burn of $24K. This gives an estimated cash runway of approximately 8011 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Sanara Medtech Inc's Piotroski F-Score?
Sanara Medtech Inc (SMTI) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Sanara Medtech Inc's earnings high quality?
Sanara Medtech Inc (SMTI) has an earnings quality ratio of 0.00x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Sanara Medtech Inc cover its interest payments?
Sanara Medtech Inc (SMTI) has an interest coverage ratio of -2.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Sanara Medtech Inc?
Sanara Medtech Inc (SMTI) scores 50 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.